Fibromyalgia (Tender Point Investigational Protocol)
Investigational adjunct targeting ACR tender points in fibromyalgia; limited case series; FDA-approved pharmacotherapy (pregabalin, duloxetine, milnacipran) and graded exercise remain primary.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for fibromyalgia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
- ¿Qué evidencia existe?
- Tier C (investigational). One small uncontrolled pilot reported short-term tender-point pain reduction; effect attenuated at 3 months. There are no randomized controlled trials. Fibromyalgia trials are highly susceptible to placebo response. Evidence-based therapies remain first-line: graded aerobic exercise (the strongest RCT support), cognitive-behavioral therapy, duloxetine, milnacipran, pregabalin, amitriptyline, sleep optimization, treatment of mood and anxiety comorbidity, and multidisciplinary pain rehabilitation. Tender-point counts have been retired from the ACR 2010 criteria in favor of widespread pain and symptom severity scores.
- Riesgos principales
- Bleeding from each bite site for 6 to 24 hours after detachment
- Bruising and tenderness across multiple body regions from widespread tender-point placement for 5 to 10 days
- Itching and irritation at bite sites for days to weeks
- Mild anemia with cumulative blood loss across repeated multi-site sessions
- Local skin or, rarely, Aeromonas hydrophila infection
- Allergic reaction to leech saliva (uncommon)
- Temporary worsening of generalized pain or fatigue (flare) for 1 to 3 days in centrally sensitized patients
- Delay of graded exercise, CBT, and evidence-based pharmacotherapy
- Quién no debería considerar esto
- Patients on blood thinners, with hemophilia, or with severe anemia
- Patients with active depression, anxiety, or PTSD that has not been addressed
- Patients with another untreated inflammatory rheumatologic condition pending workup
- Patients who have not tried graded aerobic exercise, CBT, and adequate pharmacotherapy
- Patients with a weakened immune system
- Patients with thyroid disease, sleep apnea, or vitamin D deficiency contributing to symptoms
- Patients with active dermatitis or broken skin at planned placement sites
- Qué preguntar a su clínico
- Have I been worked up for other causes (rheumatologic, thyroid, sleep apnea, vitamin D deficiency)?
- Have I completed adequate trials of graded aerobic exercise, CBT, and pharmacotherapy (duloxetine, milnacipran, pregabalin)?
- Are mood, anxiety, sleep, and stress being addressed?
- What evidence supports leech therapy specifically for fibromyalgia (versus general placebo response)?
- How will my hemoglobin be monitored given widespread multi-site sessions?
- What is the plan if I have a fibromyalgia flare after treatment?
- What is the Aeromonas-prevention protocol?
- Cuándo buscar atención urgente
- New focal weakness, sensory loss, or asymmetric joint swelling (possible alternative diagnosis)
- Severe worsening of pain or fatigue that does not resolve within a few days
- Bleeding from a bite site lasting more than 24 hours
- Spreading redness, pus, or warmth at multiple bite sites
- Fever, chills, or systemic symptoms
- Hives, facial or throat swelling, or breathing difficulty
- Severe mood deterioration, suicidal ideation, or hopelessness
Qué NO significa esto
- This is not FDA-cleared for fibromyalgia.
- One small uncontrolled pilot does not establish efficacy; fibromyalgia trials are extremely susceptible to placebo response.
- It does not replace graded aerobic exercise, CBT, or evidence-based pharmacotherapy.
- Tender-point counts were retired from the ACR 2010 criteria; the diagnostic basis of a tender-point protocol is outdated.
- Widespread multi-site bites carry cumulative anemia and infection risk that may outweigh any transient benefit.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- neurological
- ICD-10
- M79.7
- Safety tier
- medium
Evidence Summary
Fibromyalgia diagnosis follows ACR 2016 criteria. Evidence-based management includes patient education, graded aerobic exercise, cognitive-behavioral therapy, and FDA-approved pharmacotherapy (pregabalin, duloxetine, milnacipran). No controlled clinical trial of leech therapy for fibromyalgia has been published; use is investigational only, and this entry is distinct from the broader fibromyalgia record in this registry. A peripheral intervention targeting tender points is mechanistically unlikely to modify the heterogeneous central sensitization that drives fibromyalgia, and any reported benefit would be difficult to separate from placebo effects.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Michalsen A et al. (2008)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Severe allodynia at proposed treatment sites
- Concurrent SSRI/SNRI with bleeding risk concern
- Mast cell activation syndrome / sensitive skin
- Untreated mood disorder requiring psychiatric stabilization first
Related Conditions
Cervical Radiculopathy
Off-label use with one RCT (Michalsen 2018) showing significant pain reduction at 7 days in cervical radiculopathy without surgical indication.
Lumbar Radiculopathy (Sciatica)
Off-label use with controlled trial evidence (n=80) showing leg pain and Oswestry score improvement at 4-12 weeks in non-surgical lumbar disc disease.
Migraine
Investigational use with case-series evidence for reduction of migraine frequency and intensity; mechanism plausible via reduction of cervico-cranial venous congestion.
Tension-Type Headache
Investigational use with small case series suggesting frequency reduction in chronic tension headache via reduction of pericranial muscle tension and venous congestion.